**** ****** **, **** *** ● EL CAJON, CA ● 617-***-**** ● adz8xn@r.postjobfree.com

TRIVIKRAM RAJKHOWA

EDUCATION & RESEARCH

Scripps Research Institute, La Jolla, CA Feb 2023 – present

Molecular Medicine

Research Assistant 3 in the laboratory of Dr. Martin Lotz

Examined the role of various proteins for in-vitro studies using osteoarthritic cell lines and in–vivo studies using primary cells from healthy and diseased human donors.

Exelixis, Alameda, CA Oct 2022 – Jan 2023

Oncology Discovery

Scientist III

Looked at the effect of novel compounds on protein expression in breast cancer, lung cancer and melanoma cell lines.

Johns Hopkins University, Baltimore, MD Oct 2009 – Oct 2022

Department of Oncology

Sr. Research Specialist in the laboratory of Dr. Mark Levis

Assessed regulation of the Flt3 receptor in leukemic cell lines and patient primary cells.

Assessed regulation of downstream signaling components of the Flt3 receptor in leukemic cell lines.

Monitored the efficacy of FLT3 inhibition in patients enrolled in clinical trials with FLT3 inhibitors, by

using the plasma inhibitory activity (PIA) to measure Flt3 phosphorylation in leukemic cell lines.

Looked at effects of certain tyrosine kinase inhibitors on the viability of leukemic cell lines and patient primary cells.

Assessed differentiation of leukemic cell lines in response to TKIs

Processed and used blood and plasma samples in experiments from several clinical trials.

Managed ordering of reagents in the lab and was in charge of general lab maintenance and proper lab functioning.

Johns Hopkins University, Baltimore, MD Sept 2008 – Oct 2009

Department of Oncology

Research Technologist in the laboratory of Dr. Mark Levis

Assessed regulation of the Flt3 receptor (transcriptional and post-transcriptional) in leukemic cell

lines and patient primary cells.

Beth Israel Deaconess Medical Center, Boston, MA Feb 2008 – April 2008

Department of Radiation Oncology

Research Assistant in the laboratory of Dr. Chang-Yan Chen

Assessed the effects of nicotine on EGFR expression and oncogenesis in MCF-7 and MCF-10A cells.

University at Buffalo, Buffalo, NY June 2002 - Sept 2007

Department of Biochemistry

Graduate Research Assistant

M.A. in Biochemistry Thesis: Regulation of Na+/K+ ATPase in MDCK, its variants and primary renal proximal tubule cells.

Assessed regulation of Na+/K+ ATPase expression (transcriptional, post-transcriptional) in different renal cells (MDCK, DBr3 and primary renal proximal tubule cells).

Observed the regulation of renal epithelial cell growth and function.

Isolated Rabbit Primary Cell Cultures; established cell lines in hormonally defined serum free medium.

Used Rabbit Primary Cell Cultures in experimental studies.

TRIVIKRAM RAJKHOWA

University at Buffalo, Buffalo, NY Sept 2001 – June 2002

Department of Biological Sciences

Graduate Research Assistant

M.A. in Biological Sciences Thesis: Signaling in MDCK.

University of Rochester, Rochester, NY Sept 1996 – Sept 2000

Undergraduate Student

B.A. in Biology

MANUSCRIPTS

1.Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W. Burke, Harry Erba, Trisha M Wise-Draper, Gail J Roboz, Nikolaos Papadantonakis, Trivikram Rajkhowa, Daniela Hernandez, Iwona Dobler, Richard C Gregory, Cheryl Li, Shining Wang, Kate Stumpo, Karuppiah Kannan, Harry Miao and Mark Levis. A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/ refractory acute myeloid leukemia. Hematologica 2022 (1-32).

2.Theodore Karantanos, Patric Teodorescu, Brandy Perkins, Ilias Christodoulou, Christopher Esteb, Ravi Varadhan, Eric Helmenstine, Trivikram Rajkhowa, Bogdan C. Paun, Challice Bonifant, W. Brian Dalton, Lukasz P. Gondek, Alison R. Moliterno, Mark J. Levis, Gabriel Ghiaur, Richard J. Jones. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Science Advances. 8 2022 (1-11).

3.Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, Maiko Narahara, Daniela Hernandez, Trivikram Rajkhowa, Gideon Bollag, Mark Levis. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 106 2021 (1022-1033).

4. Richard T. Maziarz, Mark Levis, Mrinal M. Patnaik, Bart L. Scott, Sanjay R. Mohan, Abhinav Deol, Scott D. Rowley, Dennis D. H. Kim, Daniela Hernandez, Trivikram Rajkhowa, Kelly Haines, Gaetano Bonifacio, Patrice Rine, Das Purkayastha, Hugo F. Fernandez. Midostaurin after allogenic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation. 56 2021 (1180-1189).

5. Lauren Y Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis. Preclinical studies of gilteritinib, a next generation FLT3 inhibitor. Blood. 129 2017 (257-260).

6. E. Chang, S. Ganguly, T. Rajkhowa, C.D. Gocke, M. Levis and H.Konig. The Combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia. 30 2016 (1025-1032).

7. Mary Taub, Sudha Garimella, Dongwook Kim, Trivikram Rajkhowa, Facundo Cutuli. Renal proximal tubule Na, K-ATPase is controlled by CREB-regulated transcriptional coactivation as well as salt-inducible kinase 1. Cell Signaling. 27 2015 (2568-2578)

8. Paolo Strati, Hagop Kantarjian, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan Kadia, Zeev Estrov, Guillermo Garcia-Manero, Marina Konopleva, Trivikram Rajkhowa, Menda Durand, Michael Andreeff, Mark Levis, Jorge Cortes. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology. 90 2015 (276-281).

TRIVIKRAM RAJKHOWA

9. Yi-Bin Chen, Shuli Li, Andrew Lane, Christine Connolly, Candice Del Rio, Betsy Valles, Morgan Curtis, Karen Ballen, Corey Cutler, Bimalangshu R. Dey, Areej El-Jawahri, Amir T. Fathi, Vincent T. Ho, Amy Joyce, Steven McAfee, Michelle Rudek, Trivikram Rajkhowa, Sigitas Verselis, Joseph H. Antin, Thomas R. Spitzer, Mark Levis, Robert Soiffer. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biology of Blood and Marrow Transplantation. 12 2014 (2042-2048).

10. M. Goswami, N. Hensel, B.D. Smith, G.T. Prince, L. Qin, H.I. Levitsky, S. Anthony Strickland, M. Jagasia, B.N. Savani, J.W. Fraser, H. Sadrzadeh, T. Rajkhowa, S. Ito, N.A. Jain, M. Battiwala, A.T. Fathi, M.J. Levis, A.J. Barrett, C.S. Hourigan. Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia. 28 2014 (1167-1170).

11. Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge Cortes and Mark Levis. Crenolanib is a potent inhibitor of Flt3 with activity against resistance – conferring point mutants. Blood. 123 2013 (94-100).

12. Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia-Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan Burger, Tapan Kadia, Sara Dellasala, Michael Andreeff, Jorge Cortes, Hagop Kantarjian and Mark Levis. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation. Blood. 121 2013 (4655-4662).

13. Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E G.E. Nybakken, Keith Pratz, Judith Karp, Douglas B.D. Smith and Mark Levis. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 120 2012 (4205- 4214).

14. Amir T A.T. Fathi, Omotayo Arowojolu, Ian Swinnen, Takashi Sato, Trivikram Rajkhowa, Donald Small, Fredrik Marmsater, John E J.E. Robinson, Stefan David S.D. Gross, Matthew Martinson, Shelley Allen, Nicholas C N.C. Kallan and Mark Levis. A potential therapeutic target for FLT3-ITD AML: PIM1 Kinase. Leukemia Research. 36 2012 (224- 231).

15. Maryann B. Herman, Trivikram Rajkhowa, Facundo Cutuli, James E. Springate and Mary Taub.

Regulation of Renal Proximal Tubule Na, K-ATPase by Prostaglandins. American Journal of Physiology Renal. 298 2010 (F1222-F1234).

16. Keith W. Pratz, Takashi Sato, Kathleen Murphy, Adam Stine, Trivikram Rajkhowa and Mark Levis. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood.115 2010 (1425-1432).

17. Maryanne Borsick, Trivikram Rajkhowa, Mary Taub. Evidence for post-transcriptional regulation of Na+,K+-ATPase by prostaglandin E1. Biochemical and Biophysical Research Communications. 345 2006 (739-745).

18. Keikantse Matlhagela, Maryann Borsick, Trivikram Rajkhowa and Mary Taub. Identification of a Prostaglandin-responsive Element in the Na/K ATPase β1 promoter that is regulated by cAMP and Ca2+. The Journal of Biological Chemistry. 280 2005 (334-346).

19. Taub Mary, Borsick Maryanne, Geisel Janet, Matlhagela, Keikantse, Rajkhowa Trivikram, Allen Cheryl. Regulation of the Na, K-ATPase in MDCK cells by prostaglandin E[1]: a role for calcium as cAMP. Experimental Cell Research. 299 2004 (1-14).

TRIVIKRAM RAJKHOWA

20. Taub Mary, Ho Jae Han, Rajkhowa Trivikram, Allen Cheryl, Jun Hong Park. Clonal analysis of immortalized renal proximal Tubule cells: Na glucose cotransport system levels are maintained despite a decline in transport function. Experimental Cell Research. 281 2002 (205-212).

POSTER SESSIONS & PRESENTATIONS

Poster Sessions

1.55th Ash Annual Meeting and Exposition, New Orleans, LA 2013. Pharmacodynamic Analysis of the Inhibitory Potency of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. Sabine Kayser, Mark Levis, Carina Morlok, Andrea Kuendgen, Michael Heuser, Walter Fiedler, Joerg Westermann, Katharina Goetze, Helmut R. Salih, Andreas L. Petzer, Frank Hartmann, Heinz A. Horst, Uwe M. Martens, Gerald Wulf, Michael Luebbert, Dominik Wolf, Richard Greil, Claus-Henning Koehne, Mark Ringhoffer, Hartmut Kirchner, Michael Pfreundschuh, Brigitte Schlegelberger, Patricia Erdmann, Trivikram Rajkhowa, Peter Paschka, Verena I. Gaidzik, Veronica Teleanu, Felicitas Thol, Arnold Ganser, Hartmut Doehner, Konstanze Doehner, Richard F. Schlenk. Molecular Pharmacology, Drug Resistance: Poster I. Johns Hopkins Medical Institute, Baltimore, MD.

2.54th Ash Annual Meeting and Exposition, Atlanta, GA. Fall 2012. Crenolanib is a Highly Potent, Selective FLT3 TKI with Activity Against D835 Mutations. Allison Galanis, Trivikram Rajkhowa, Chaitanya Muralidhara, Abhijit Ramachandran and Mark Levis. Molecular Pharmacology, Drug Resistance: Poster I. Johns Hopkins Medical Institute, Baltimore, MD.

3.53rd Ash Annual Meeting and Exposition, San Diego, CA. Fall 2011. The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML. Elizabeth Burton, Bernice Wong, Jiazhong Zhang, Brian West, Gideon Bollag, Gaston Habets, Allison Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram

Rajkhowa and Mark Levis. Acute Myeloid Leukemia, Therapy excluding Transplantation: Poster III. Johns Hopkins Medical Institute, Baltimore, MD.

4.51st Ash Annual Meeting and Exposition, New Orleans, LA. Fall 2009. FLT3 Mutant to Wild Type Allelic Ratio and Clinical Status Are Predictive of Response to FLT3 Inhibitors in AML.

Mark Levis, Takashi Sato, Kathleen Murphy, Trivikram Rajkhowa and Keith Pratz. Molecular Pharmacology, Johns Hopkins Medical Institute, Baltimore, MD.

5.51st Ash Annual Meeting and Exposition, New Orleans, LA. Fall 2009. PIM: An Integral Component of FLT3 Signaling and a Potential Therapeutic Target in Acute Myeloid Leukemia.

Amir T. Fathi, Ian Swinnen, Trivikram Rajkhowa, Donald Small, Fredrick Marmaster, John E Robinson, Stefan David Gross, Matthew Martinson, Shelley Allen, Nick Kallan and Mark Levis. Molecular Pharmacology, Johns Hopkins Medical Institute, Baltimore, MD.

6.Pediatric Academic Societies Annual Meeting. Philadelphia, PA; Toronto Ca. Spring 2007. Chronic Exposure to Dopamine Stimulates Na+K+ATPase Pump in Proximal Tubule Cells. Sudha Garimella-Krovi, Triv Rajkhowa, James Springate, Mary Taub. Nephrology, Children’s Hospital, Buffalo, NY; Biochemistry. University at Buffalo, Buffalo, NY.

7.Leon Farhi Symposium, Fall 2005. Regulation of the Na+/K+ ATPase in MDCK and variant MDCK cells. Trivikram Rajkhowa, Mary Taub. University at Buffalo, Buffalo, NY.

TRIVIKRAM RAJKHOWA

8.Biochemistry Annual Research Day. Buffalo, NY. Summer 2004. The Na+/K+ATPase and the Role of PKC, PKA and other signaling pathways in MDCK. Trivikram Rajkhowa, Mary Taub. University at Buffalo, Buffalo, NY.

9.Biochemistry Annual Research Day. Buffalo, NY. Summer 2003. Assessment of the role of the MAP Kinase and PI3 Kinase pathways in mediating growth factor effects on kidney epithelial cells through expression of a constitutively active MAP Kinase Kinase. Trivikram Rajkhowa, Mary Taub. University at Buffalo, Buffalo, NY.

Presentations

1.56th Ash Annual Meeting and Exposition, San Francisco, CA, Fall 2014. Phase I trial of maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation For Patients with FLT3-ITD AML.

Yi-Bin Chen, Shuli Li, Andrew Lane, Christine Connolly, Candice Del Rio, Betsy Valles, Morgan Curtis, Karen Ballen, Corey Cutler, Bimalangshu R. Dey, Areej El-Jawahri, Amir T. Fathi, Vincent T. Ho, Amy Joyce, Steven McAfee, Michelle Rudek, Trivikram Rajkhowa, Sigitas Verselis, Joseph H. Antin, Thomas R. Spitzer, Mark Levis, Robert Soiffer. Johns Hopkins Medical Institute, Baltimore, MD.

2.52nd Ash Annual Meeting and Exposition, Orlando, FL, Fall 2010. FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220. Mark Levis, Amy Sexauer, Trivikram Rajkhowa, Donald Small, Michael Borowitz. Johns Hopkins Medical Institute, Baltimore, MD.

3.Biochemistry Annual Research Day. Buffalo, NY. Summer 2006. Regulation of the Na+/K+ATPase in primary proximal tubule cells. Trivikram Rajkhowa, Mary Taub. Univ.at Buffalo, Buffalo, NY.

4.Biochemistry Annual Research Day. Buffalo, NY. Summer 2005. Regulation of the Na+/K+ATPase in cultured epithelial cells. Trivikram Rajkhowa, Mary Taub. University at Buffalo, Buffalo, NY.

TECHNIQUES

Western Blot Analysis

PIA (Plasma Inhibitory Assay)

ELISA

Chemiluminescence

Cell Surface Biotinylation

Transient Transfection – promoter analysis using luciferase assay system

Virus Transduction

Cell Growth Studies

MTT Assays

Molecular Cloning

Fluorescence Microscopy

Tissue Culture

Biorad Protein Assay

Bone Marrow Stromal Culture

Primary Cell Culture (cells isolated from the kidneys of adult New Zealand rabbits)

G418 Titration

DNA restriction digest/ gel electrophoresis

DNA Preps

PCR

RT-PCR

qPCR

TRIVIKRAM RAJKHOWA

COMPUTER SKILLS

Statistical Analysis: GraphPad Prizm 4, Image Analysis: Quantity One (Quantitation Scanning densitometry), Image J, MS Office, Adobe Photoshop, Kaleidograph, Li-Cor Machine, Calcusyn, Microplate Manager.

TRIVIKRAM RAJKHOWA

REFERENCES

1.Dr. Martin Lotz, Professor. Molecular and Cellular Biology

Address – 10550 North Torrey Pines Rd, La Jolla, CA 92037

e-mail – adz8xn@r.postjobfree.com

Phone – 858-***-****

2.Dr. Mark Levis, Professor. Oncology

Address – SKCC at Johns Hopkins, 1650 Orleans Street, CRB1 Room 2M44, Baltimore, MD 21231

e-mail – adz8xn@r.postjobfree.com

Phone – 410-***-****

3.Dr. Gabriel Ghiaur, Associate Professor of Oncology

Address - SKCC at Johns Hopkins, 1650 Orleans St, CRB1 Room 243, Baltimore, MD 21231

e-mail – adz8xn@r.postjobfree.com

phone – 410-***-****

Contact this candidate